• J Natl Compr Canc Netw · Feb 2015

    Practice Guideline

    Kidney cancer, version 3.2015.

    • Robert J Motzer, Eric Jonasch, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B Bolger, Sam S Chang, Toni K Choueiri, Brian A Costello, Ithaar H Derweesh, Shilpa Gupta, Steven L Hancock, Jenny J Kim, Timothy M Kuzel, Elaine T Lam, Clayton Lau, Ellis G Levine, Daniel W Lin, M Dror Michaelson, Thomas Olencki, Roberto Pili, Elizabeth R Plimack, Edward N Rampersaud, Bruce G Redman, Charles J Ryan, Joel Sheinfeld, Brian Shuch, Kanishka Sircar, Brad Somer, Richard B Wilder, Mary Dwyer, Rashmi Kumar, and National comprehensive cancer network.
    • From Memorial Sloan Kettering Cancer Center; The University of Texas MD Anderson Cancer Center; Huntsman Cancer Institute at the University of Utah; Dana-Farber/Brigham and Women's Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; University of Alabama at Birmingham Comprehensive Cancer Center; Vanderbilt-Ingram Cancer Center; Mayo Clinic Cancer Center; UC San Diego Moores Cancer Center; Moffitt Cancer Center; Stanford Cancer Institute; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; University of Colorado Cancer Center; City of Hope Comprehensive Cancer Center; Roswell Park Cancer Institute;University of Washington/Seattle Cancer Care Alliance; Massachusetts General Hospital Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Fox Chase Cancer Center; Duke Cancer Institute; University of Michigan Comprehensive Cancer Center; UCSF Helen Diller Family Comprehensive Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; and National Comprehensive Cancer Network.
    • J Natl Compr Canc Netw. 2015 Feb 1; 13 (2): 151-9.

    AbstractThe NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non-clear cell renal carcinoma. These NCCN Guidelines Insights highlight the recent updates/changes in these guidelines, and updates include axitinib as first-line treatment option for patients with clear cell renal carcinoma, new data to support pazopanib as subsequent therapy for patients with clear cell carcinoma after first-line treatment with another tyrosine kinase inhibitor, and guidelines for follow-up of patients with renal cell carcinoma.Copyright © 2015 by the National Comprehensive Cancer Network.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…